Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2015 Sep;44(3):559-64. doi: 10.1016/j.ecl.2015.05.005. Epub 2015 Jun 22.

Menopause and the Heart.

Author information

1
Penn Heart and Vascular Center for Women's Cardiovascular Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
2
Section of Cardiovascular Medicine, Yale Cardiovascular Research Center, Raymond and Beverly Sackler Cardiovascular Laboratory, Yale University School of Medicine, 300 George Street, Room 773G, New Haven, CT 06511, USA. Electronic address: jeffrey.bender@yale.edu.

Abstract

Cardiovascular disease is the leading cause of death in postmenopausal US women. The contribution of postmenopausal hormone replacement therapy to cardiovascular risk is one of the most controversial women's health topics. Strikingly discordant results, between observational and randomized clinical trials, have been reported. Remaining questions regarding time of hormone therapy initiation are discussed, as are ongoing trials focused on these questions. Cardiovascular concerns, cautions, and current recommendations for use are delineated.

KEYWORDS:

Cardiovascular risk; Heart; Hormone replacement therapy; Menopause

PMID:
26316243
DOI:
10.1016/j.ecl.2015.05.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center